157 related articles for article (PubMed ID: 38167017)
1. Development and validation of a disulfidptosis and disulfide metabolism-related risk index for predicting prognosis in lung adenocarcinoma.
Zhong L; Chang W; Luo B; Gao W; He H; Fang M; Li H; Wen Z; Chen Y
Cancer Cell Int; 2024 Jan; 24(1):2. PubMed ID: 38167017
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a disulfidptosis-related genes prognostic signature in lung adenocarcinoma.
Zhang Y; Sun J; Li M; Hou L; Wang Z; Dong H; Xu W; Jiang R; Geng Y; Guan C; Zhu Z; Wang H; Gong Q; Zhang G
Heliyon; 2024 Jan; 10(1):e23502. PubMed ID: 38223725
[TBL] [Abstract][Full Text] [Related]
3. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
4. A disulfidptosis-related lncRNA prognostic model to predict survival and response to immunotherapy in lung adenocarcinoma.
Zhang HB; Pan JY; Zhu T
Front Pharmacol; 2023; 14():1254119. PubMed ID: 37822882
[No Abstract] [Full Text] [Related]
5. Investigating the prognostic value of constructing disulfidptosis-related gene models for lung adenocarcinoma patients.
Luo M; Liu RZ; Li YJ; Zhang SD; Wu ZY
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9569-9585. PubMed ID: 37916324
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
8. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
10. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y; Kong X; Mei H; Wang J; Zhou S
Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.
Zhong F; Jiang J; Yao FY; Liu J; Shuai X; Wang XL; Huang B; Wang X
Front Pharmacol; 2023; 14():1272701. PubMed ID: 38053840
[No Abstract] [Full Text] [Related]
13. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
14. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma.
Xue W; Qiu K; Dong B; Guo D; Fu J; Zhu C; Niu Z
Cancer Cell Int; 2023 Sep; 23(1):218. PubMed ID: 37759294
[TBL] [Abstract][Full Text] [Related]
15. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning.
Wang Z; Du X; Lian W; Chen J; Hong C; Li L; Chen D
Front Genet; 2023; 14():1193944. PubMed ID: 37456667
[No Abstract] [Full Text] [Related]
16. Identification of a disulfidptosis-related genes signature for prognostic implication in lung adenocarcinoma.
Huang J; Zhang J; Zhang F; Lu S; Guo S; Shi R; Zhai Y; Gao Y; Tao X; Jin Z; You L; Wu J
Comput Biol Med; 2023 Oct; 165():107402. PubMed ID: 37657358
[TBL] [Abstract][Full Text] [Related]
17. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma.
Qi C; Ma J; Sun J; Wu X; Ding J
Aging (Albany NY); 2023 Jun; 15(11):5075-5095. PubMed ID: 37315289
[TBL] [Abstract][Full Text] [Related]
18. Exploring the role of disulfidptosis-related signatures in immune microenvironment, prognosis and therapeutic strategies of cervical cancer.
Jin T; Yin T; Xu R; Liu H; Yuan S; Xue Y; Zhang J; Wang H
Transl Oncol; 2024 Jun; 44():101938. PubMed ID: 38492499
[TBL] [Abstract][Full Text] [Related]
19. The expression and prognostic value of disulfidptosis progress in lung adenocarcinoma.
Ni L; Yang H; Wu X; Zhou K; Wang S
Aging (Albany NY); 2023 Aug; 15(15):7741-7759. PubMed ID: 37552140
[TBL] [Abstract][Full Text] [Related]
20. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
